外用褪黑激素 Topical Melatonin × 雄性禿
Topical melatonin for AGA rests on a thin evidence base with a weak but directionally positive signal.
Topical melatonin for AGA rests on a thin evidence base with a weak but directionally positive signal. The core study is Fischer 2004 (PMID 14996107), a small double-blind placebo-controlled pilot RCT (n=40, but the AGA subgroup is only ~12) showing a significant increase in occipital anagen hair rate vs placebo (P=0.012); however the sample is small, the population mixes AGA with diffuse alopecia, and Sladden 2005 (PMID 16181483, Br J Dermatol) published a critical appraisal questioning the multiplicity of comparisons and clinical relevance. Fischer 2012 (PMID 23766606, Int J Trichology) reports larger positive effects (~29-41% hair density increase) but draws on open-label / pre-post / observational designs by an investigator linked to the product — high bias risk, not efficacy-establishing. The 2025 Gupta network meta-analysis (PMID 41051009) lists topical melatonin only as a non-conventional OTC alternative inferior to minoxidil/finasteride. No large multicenter placebo-controlled RCT exists. NIH/NCCIH, Mayo, Cleveland, Harvard, and AAD do NOT address or endorse topical melatonin for AGA — their AGA guidance lists only minoxidil and finasteride (FDA-approved). FDA has not approved any topical melatonin hair product; Taiwan TFDA classifies all melatonin-labeled products (oral OR topical) as drugs, so a topical melatonin hair lotion cannot be legally retailed in Taiwan. This is a textbook Tier C case: plausible mechanism + a small amount of directionally consistent human evidence, but low study quality, industry bias, no mainstream endorsement, and not a substitute for finasteride/minoxidil.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.539
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
台灣掉髮社群（PTT hair_loss 板、Dcard、Mobile01）對『外用褪黑激素治療雄性禿』之討論幾近於無——社群討論壓倒性集中於 finasteride（柔沛/波斯卡）、dutasteride（新髮靈）與外用 minoxidil（落健生髮水），此三者為衛福部核准之治禿藥物。褪黑激素在台灣社群多被討論為『口服助眠』議題，與外用養髮幾乎無連結；偶有少數養髮品牌行銷或內容站提及褪黑激素養髮精華，但缺乏具規模的鄉民實測心得或共識。整體屬冷門、低能見度議題，無明顯社群口碑，亦無顯著業配密度（相較 minoxidil/finasteride 之高討論度）。在台因 melatonin 列藥品管理，外用養髮產品多需海外自購，進一步降低社群討論基礎。
資料極少／無共識——台灣掉髮社群幾乎不討論外用褪黑激素，主流選項為 finasteride/dutasteride/minoxidil；無具規模的鄉民實測心得可歸納
- （社群資料極少；外用褪黑激素之臨床研究報告局部副作用輕微、耐受性良好，但非台灣社群實測歸納）
依論壇被提及頻率，非銷售或品質排序。
- （台灣社群無明顯主流外用褪黑激素養髮品牌；偶見海外 melatonin hair serum 海外自購提及，泛指）
⚠️ 列出僅代表「TW 社群討論度高」，不代表本站推薦或背書。本站不販售任何產品、無導購連結。
- 外用 Minoxidil（落健）
- 口服 Finasteride（柔沛）
- 低能量雷射治療（LLLT）
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-androgenetic-alopecia-INT-topical-melatonin-001/",
"datePublished": "2026-06-02",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "外用褪黑激素能改善雄性禿",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}